About this trial
The goal of this study is to assess the frequency of genetic polymorphisms of the FCG3A in a cohort of Italian patients affected by neuromyelitis optica spectrum disorder (NMOSD) and mog antibody associated disease (MOGAD) and in a a comparison group of patients affected with Multiple Sclerosis (MS).
The study will involve adult patients diagnosed with MS, NMOSD, or MOGAD, followed at various clinical centers in the Lazio region.
Patients from the participating clinical centers will be selected, and their medical records will be analyzed to collect clinical and neuroimaging data. The data will include demographic information such as age, sex and body mass index and clinical information such as age at disease onset, disease duration, antibody status (AQP4+/- and MOG+/-), disease-modifying therapies, as well as MRI data and the Expanded Disability Status Scale (EDSS) score.
Each patient included in the study will undergo a single blood draw of approximately 5 ml of peripheral venous blood during routine blood tests, which will be used for DNA extraction and polimorphysm analysis. Demographic and clinical differences between patients with NMOSD and MOGAD, with and without the polymorphism, will be assessed and compared with the group of patients with MS.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult patients diagnosed with MS, NMOSD, or MOGAD receiving care at participating centers
Patients aged ≥ 18 years
Ability to understand and sign informed consent
Disqualifiers
Individuals under 18 years of age
Inability to provide informed consent
Trial design
Parallel
Treatments tested in this trial
Blood draw for the laboratory assessment
Procedure/SurgeryBlood draw of approximately 5 ml of peripheral venous blood (collected in EDTA) will be collected for DNA extraction and genetic analysis limited to the research of FCG3A polymorphisms
Treatment groups
Trial outcomes
Primary outcomes
FCGR3A gene polymorphism frequency in a cohort of Italian patients affected by NMOSD and MOGAD.
To assess the frequency of the FCGR3A gene polymorphism in a cohort of Italian patients affected by NMOSD and MOGAD.
Secondary outcomes
Clinical characteristics of NMOSD and MOGAD patients who express the polymorphism
Disability assessed by Expanded disability status scale in NMOSD and MOGAD patients who express the polymorphism and in to those who do not.
Clinical characteristics of NMOSD and MOGAD patients who express the polymorphism
Number of disease relapses in patients with NMOSD and MOGAD expressing the polymorphisms and in patients without the polymorphism
Sponsors and contacts
Click on the lead sponsor to view all of their trials.